The second in our series of guest episodes features a discussion between CEO of Releaf, Tim Kirby, and James Duckenfield, CEO of Glass Pharms. Tim & James discuss the challenges and progress within the UK's medical cannabis industry since its legalisation in 2018, highlighting the previous stagnation due to various factors including inconsistent supply chains and a lack of a healthcare-focused approach. The discussion emphasises the importance of quality, consistency, and patient outcomes, showcasing how their collaboration aims to provide reliable medical cannabis to patients. They also touch upon the regulatory landscape, the need for better education for doctors, and the potential for significant growth in the UK market by addressing unmet healthcare needs.